High-risk medulloblastoma: Does c-myc amplification overrule histopathology?

Pediatric Blood and Cancer

Volumn 54, Issue 3, 2010, Pages 344-345

  Raabe, Eric H ^a   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC CARCINOMA; CANCER RISK; CANCER SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; METASTASIS; ONCOGENE C MYC; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; GENE AMPLIFICATION; GENES, MYC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDULLOBLASTOMA; NEOPLASM METASTASIS; RISK FACTORS; YOUNG ADULT;

EID: 76749094506     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22398     Document Type: Short Survey

References (15)

1. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24: 4202-4208.
2. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-1636.
3. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-385.
4. Giangaspero F, Eberhart CG, Haapasalo H, et al. Medulloblastoma. In: Louis DN, Hirolo O,Wiester OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer; 2007. pp. 132-140.
5. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
6. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-865.
7. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 2002;94:552-560.
8. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-449.
9. Giangaspero F, Wellek S, Masuoka J, et al. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 2006;112:5-12.
10. Min HS, Lee YJ, Park K, et al. Medulloblastoma: Histopathologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol 2006;112:13-20.
11. Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-2485.
12. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001; 7:2425-2433.
13. von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009;45:1209-1217.
14. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
15. von Bueren AO, Shalaby T, Oehler-Janne C, et al. RNA interference- mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer 2009;9:10.